Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study (CROSBI ID 203090)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kolumbić Lakoš, Adela ; Škerk, Višnja ; Maleković, Goran ; Dujnić Špoljarević, Tatjana ; Kovačić, Dražen ; Pasini, Miram ; Markotić, Alemka ; Magri, V. ; Perletti, G. A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study // Journal of chemotherapy, 23 (2011), 6; 350-353. doi: 10.1179/joc.2011.23.6.350

Podaci o odgovornosti

Kolumbić Lakoš, Adela ; Škerk, Višnja ; Maleković, Goran ; Dujnić Špoljarević, Tatjana ; Kovačić, Dražen ; Pasini, Miram ; Markotić, Alemka ; Magri, V. ; Perletti, G.

engleski

A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study

(CBP) is characterized by intense clinical symptoms, frequent relapse episodes and poor quality of life. Aggressive antibacterial therapy is warranted to eradicate the causative pathogens and to achieve a permanent cure. We administered a "switch-therapy" protocol to 30 patients showing severe CBP symptoms and two or more relapse episodes in the previous 12 months. Patients received intravenous azithromycin (500 mg/day) and ciprofloxacin (800 mg/day) for 3 days, followed by oral ciprofloxacin (1 g/day) for 25 days.Twenty-seven (90%) patients showed pathogen eradication at test-of-cure (TOC) visit. Five cases of infection relapse were detected at follow-up. At the TOC visit, 25 patients (83%) showed mild/absent symptoms, measured with the NIH-chronic prostatitis symptom index.These results indicate the efficacy of a "switch-therapy" protocol, based on combined azithromycin and ciprofloxacin. Comparative studies on larger CBP patient populations are warranted to confirm these encouraging results

Chronic bacterial prostatitis; antibacterial therapy; pilot study

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

23 (6)

2011.

350-353

objavljeno

1120-009X

10.1179/joc.2011.23.6.350

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost